BR0113902A - Processo de contracepção e forma de administração do mesmo - Google Patents

Processo de contracepção e forma de administração do mesmo

Info

Publication number
BR0113902A
BR0113902A BR0113902-9A BR0113902A BR0113902A BR 0113902 A BR0113902 A BR 0113902A BR 0113902 A BR0113902 A BR 0113902A BR 0113902 A BR0113902 A BR 0113902A
Authority
BR
Brazil
Prior art keywords
taking
administration
period
contraception
phase
Prior art date
Application number
BR0113902-9A
Other languages
English (en)
Inventor
Hermann Kulmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0113902A publication Critical patent/BR0113902A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

"PROCESSO DE CONTRACEPçãO E FORMA DE ADMINISTRAçãO DO MESMO". A presente invenção refere-se a um processo para contracepção hormonal, em que uma série de períodos de tomada ligados, substancialmente não limitados ao tempo, e opcionalmente, com uma seq³ência que dura vários anos e que, em cada caso compreende pelo menos um ciclo de tomada com uma fase de tomada constante perdurando vários dias dentro do período particular de tomada, e uma pausa da tomada que perdura vários dias, em que ocorre a fase ou fases de tomada por administração diária, de uma unidade com pelo menos um componente hormonal de ação contraceptiva, como um estrógeno e/ou gestágeno, e na pausa ou pausas de tomada ocorre a administração de quaisquer placebos isentos de qualquer componente hormonal ou a pausa de tomada particular, permanece inteiramente isenta de administração e a duração da fase ou fases de tomada de pelo menos um período de tomada final dura pelo menos 22 dias, caracterizado pelo fato da duração da fase ou fases de tomada em qualquer período de tomada precedente a um período de tomada seguinte ser mais curta do que em cada caso seguinte ao período de tomada, bem como a forma de administração para contracepção hormonal e, em particular para a realização da mesma.
BR0113902-9A 2000-09-14 2001-09-05 Processo de contracepção e forma de administração do mesmo BR0113902A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045380A DE10045380A1 (de) 2000-09-14 2000-09-14 Verfahren zur Kontrazeption und dessen Darreichungsform
PCT/EP2001/010207 WO2002022110A2 (en) 2000-09-14 2001-09-05 Contraception process and administration form for the same

Publications (1)

Publication Number Publication Date
BR0113902A true BR0113902A (pt) 2003-07-22

Family

ID=7656125

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113902-9A BR0113902A (pt) 2000-09-14 2001-09-05 Processo de contracepção e forma de administração do mesmo

Country Status (31)

Country Link
US (2) US8076317B2 (pt)
EP (2) EP1317286B1 (pt)
JP (3) JP2004508398A (pt)
KR (3) KR20090033502A (pt)
CN (1) CN100560132C (pt)
AR (1) AR030737A1 (pt)
AT (1) ATE447972T1 (pt)
AU (2) AU8405201A (pt)
BG (2) BG107625A (pt)
BR (1) BR0113902A (pt)
CA (1) CA2420292C (pt)
CZ (1) CZ2003723A3 (pt)
DE (2) DE10045380A1 (pt)
EA (1) EA006875B1 (pt)
EE (1) EE200300103A (pt)
HR (1) HRP20030294A2 (pt)
HU (1) HUP0301042A3 (pt)
IL (2) IL154521A0 (pt)
ME (1) ME00291B (pt)
MX (1) MXPA03002070A (pt)
NO (1) NO20031152L (pt)
NZ (1) NZ524448A (pt)
PE (1) PE20020425A1 (pt)
PL (1) PL361161A1 (pt)
SK (1) SK3102003A3 (pt)
TW (1) TWI297271B (pt)
UA (1) UA93650C2 (pt)
UY (1) UY26932A1 (pt)
WO (1) WO2002022110A2 (pt)
YU (1) YU19003A (pt)
ZA (1) ZA200301359B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
AU2011226911B2 (en) * 2004-04-30 2014-06-19 Bayer Intellectual Property Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
TW200744610A (en) * 2005-06-21 2007-12-16 Organon Nv New regimens for controlled drug delivery devices for contraception
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
GB0623813D0 (en) * 2006-11-29 2007-01-10 Stephenson Group Ltd Foam reduction
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2365103C3 (de) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP1488794A3 (en) * 1994-11-22 2005-04-20 Balance Pharmaceuticals, Inc. Methods of contraception
DE19525017A1 (de) 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
WO1998004269A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Also Published As

Publication number Publication date
UA93650C2 (ru) 2011-03-10
HUP0301042A3 (en) 2010-03-29
AU8405201A (en) 2002-03-26
NZ524448A (en) 2005-03-24
HUP0301042A2 (hu) 2003-10-28
EP2153849A3 (en) 2011-09-14
BG107625A (bg) 2003-11-28
UY26932A1 (es) 2001-12-28
KR20090033502A (ko) 2009-04-03
MXPA03002070A (es) 2003-06-24
EA200300338A1 (ru) 2003-08-28
MEP37608A (en) 2011-02-10
EE200300103A (et) 2005-02-15
NO20031152D0 (no) 2003-03-13
ME00291B (me) 2011-05-10
HK1060305A1 (zh) 2004-08-06
US8536156B2 (en) 2013-09-17
EP2153849A2 (en) 2010-02-17
CN100560132C (zh) 2009-11-18
AU2001284052B2 (en) 2006-11-30
EA006875B1 (ru) 2006-04-28
CA2420292A1 (en) 2002-03-21
ATE447972T1 (de) 2009-11-15
PL361161A1 (en) 2004-09-20
PE20020425A1 (es) 2002-06-15
CA2420292C (en) 2010-12-14
JP2004508398A (ja) 2004-03-18
SK3102003A3 (en) 2003-09-11
US20120129823A1 (en) 2012-05-24
DE10045380A1 (de) 2002-04-04
HRP20030294A2 (en) 2005-02-28
KR20030031185A (ko) 2003-04-18
IL154521A0 (en) 2003-09-17
US8076317B2 (en) 2011-12-13
IL154521A (en) 2014-05-28
BG111090A (bg) 2012-03-30
TWI297271B (en) 2008-06-01
US20040219174A1 (en) 2004-11-04
ZA200301359B (en) 2004-02-05
DE60140462D1 (de) 2009-12-24
WO2002022110A2 (en) 2002-03-21
CN1455681A (zh) 2003-11-12
KR20100056577A (ko) 2010-05-27
JP2013006866A (ja) 2013-01-10
JP2013241456A (ja) 2013-12-05
NO20031152L (no) 2003-05-14
KR101240232B1 (ko) 2013-03-07
EP1317286B1 (en) 2009-11-11
AR030737A1 (es) 2003-09-03
YU19003A (sh) 2006-05-25
CZ2003723A3 (cs) 2003-06-18
WO2002022110A3 (en) 2002-07-04
EP1317286A2 (en) 2003-06-11

Similar Documents

Publication Publication Date Title
BR0113902A (pt) Processo de contracepção e forma de administração do mesmo
BR0304411A (pt) Processo para a produção de efeitos de memória de moldagem sobre cabelos mediante combinação de polìmeros de memória de moldagem com substâncias ativas cationativas
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
BR112021023240A2 (pt) Método para gerar um modelo de arcada dentária
Axel et al. Pro-drop in the history of German from Old High German to the modern dialects
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
Li et al. Reversal of scopolamine induced amnesia in rats by the steroid sulfatase inhibitor estrone-3-O-sulfamate
NO970309L (no) Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri
AR018178A1 (es) Derivados de cromanona y tiocromanona, un proceso para su preparacion, una composicion farmaceutica que los comprende y el uso de los mismos para lapreparacion de un medicamento
BR9710566A (pt) M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
ATE293979T1 (de) Pharmazeutische zusammensetzungen enthaltend syntethisch natürliche progesteron und estradiol und verfahren zur herstellung derselben
BR0300301A (pt) Método para afetar comportamentos durante o sono e relacionados ao sono
US20090137537A1 (en) Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
Kochman et al. Circadian variation in mouse hippocampal cell proliferation
BR0309595A (pt) Injeção produzida a partir de ixeris sonchifolia hance para o tratamento de doenças vasculares cardiocerebrais e doenças de fundo, e método para a produção da mesma
EA199700282A1 (ru) Азатиоприновые композиции для введения в толстую кишку
MX2007004120A (es) Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
JP2004261599A5 (pt)
BRPI0414945A (pt) regimes contraceptivos trifásicos estendidos
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
RS51434B (sr) Višefazni preparat za kontracepciju na bazi prirodnog estrogena
BR0318192A (pt) regimes contraceptivos transdérmicos prolongados
BR0206361A (pt) Método de terapia de reposição de hormÈnio e sua forma de administração
Morin et al. Independence of progesterone-induced facilitation and inhibition of lordosis behavior in ovariectomized guinea pigs

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 15 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25B Requested transfer of rights rejected

Owner name: SCHERING AKTIENGESELLSCHAFT (DE)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870170016753 DE 14/03/2017, CONFORME DISPOSTO NO ART. 59 DA LEI 9279 DE 14/05/1996, PELO FATO DO PEDIDO DE PATENTE TER SIDO INDEFERIDO NA RPI 2077 DE 26/10/2010 COM DECISAO MANTIDA EM GRAU DE RECURSO PUBLICADO NA RPI 2281 DE 23/09/2014.

Owner name: SCHERING AKTIENGESELLSCHAFT (DE)

B25E Requested change of name of applicant rejected

Owner name: SCHERING AKTIENGESELLSCHAFT (DE)

B15G Petition not considered as such [chapter 15.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]